Enzon Pharmaceuticals Inc. (ENZN)
-NasdaqGS 1.68 
0.02(1.18%) 10:49AM EDT - Nasdaq Real Time Price
| Prev Close: | 1.70 |
|---|
| Open: | 1.70 |
|---|
| Bid: | 1.68 x 1500 |
|---|
| Ask: | 1.69 x 1700 |
|---|
| 1y Target Est: | 14.00 |
|---|
| Beta: | 0.98 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 1.69 - 1.73 |
|---|
| 52wk Range: | 1.54 - 7.47 |
|---|
| Volume: | 22,371 |
|---|
| Avg Vol (3m): | 366,673 |
|---|
| Market Cap: | 73.46M |
|---|
| P/E (ttm): | 112.00 |
|---|
| EPS (ttm): | 0.02 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Alex Denner Joins Vivus Activist Slate in Post-Icahn Moveat Bloomberg(Thu, May 23)
- ENZN July Options Begin Tradingat TheStreet(Mon, May 20)
- ENZON PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Special Dividend and Ongoing Cash Distributionat Motley Fool(Tue, May 14)
- Billionaire Seth Klarman's Long-Term Stock Picksat Seeking Alpha(Mon, May 13)
- Seth Klarman's Worst Performing Stock Picks Year-To-Dateat Seeking Alpha(Mon, May 13)
- ENZON PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other EventsEDGAR Online(Mon, May 6)
- ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Apr 23)
- Enzon concludes review of possible asset sale, sale of company, announces special dividendtheflyonthewall.com(Tue, Apr 23)
- Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty DividendsMarketwired(Tue, Apr 23)
- ENZON PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal ActivitiesEDGAR Online(Tue, Mar 26)
- Enzon Reports Fourth Quarter and Full Year 2012 ResultsMarketwired(Mon, Mar 18)
- ENZON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Mon, Mar 18)
- ENZON PHARMACEUTICALS INC Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Mar 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1.79 |
|---|
| Ex-Dividend Date: | 05-Jun-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Enzon Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the research and development of therapeutics for patients with unmet medical needs.
View More